Ashley McKinney
Family · Bean Station, TNNPI 1184123382
Payments from drug & device makers
Across 226 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$791
- Otsuka America Pharmaceutical, Inc.$621
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$483
- Axsome Therapeutics, Inc.$206
- Lundbeck LLC$168
- Vanda Pharmaceuticals Inc.$164
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $791 |
| Otsuka America Pharmaceutical, Inc. | 39 | $621 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $483 |
| Axsome Therapeutics, Inc. | 11 | $206 |
| Lundbeck LLC | 9 | $168 |
| Vanda Pharmaceuticals Inc. | 9 | $164 |
| Novo Nordisk | 7 | $150 |
| Almatica Pharma LLC | 8 | $132 |
| GSK | 7 | $102 |
| Gilead | 5 | $88 |
| Pfizer | 6 | $82 |
| AstraZeneca | 3 | $55 |
| Lilly USA, LLC | 3 | $51 |
| Alkermes, Inc. | 2 | $45 |
| Banner Life Sciences, LLC | 2 | $41 |
| Amgen | 1 | $31 |
| Biogen | 1 | $29 |
| Dexcom, Inc. | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| Merck | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Sanofi | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$3,459 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 166 | $232,910 |
| OzempicSemaglutide | 83 | $98,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $90,307 |
| Dupixent SyringeDupilumab | 19 | $77,276 |
| Abilify MaintenaAripiprazole | 28 | $75,642 |
| RybelsusSemaglutide | 30 | $53,459 |
| TrulicityDulaglutide | 50 | $51,940 |
| UbrelvyUbrogepant | 34 | $48,148 |
| LinzessLinaclotide | 47 | $47,776 |
| MounjaroTirzepatide | 34 | $41,370 |
| Nurtec OdtRimegepant Sulfate | 20 | $34,575 |
| JardianceEmpagliflozin | 29 | $24,466 |
| VivitrolNaltrexone Microspheres | 12 | $19,750 |
| CaplytaLumateperone Tosylate | 11 | $19,487 |
| EliquisApixaban | 21 | $19,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Linzess, Creon | $791 | $344,422260 claims |
| Novo NordiskOzempic, Rybelsus | $150 | $152,272113 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $102 | $94,781115 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $51 | $93,30984 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $621 | $75,64228 claims |
| PfizerNurtec Odt, Eliquis | $82 | $53,85241 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $55 | $45,46766 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $15 | $44,13966 claims |
| Alkermes, Inc.Vivitrol | $45 | $19,75012 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $483 | $19,48711 claims |
| MerckJanuvia | $18 | $18,97822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.
Other family in Bean Station
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.